Q BioMed Adds Big Pharma Executive to Board of Directors

Veteran Novartis and WuXii Global Head of Pharmaceutical Development Joins Company BoardNEW YORK, February 13, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to welcome Dr. Rick Panicucci as an independent member on...

Q Biomed Inc. Closes $5.48 Million Public Offering

Company Expects Commercialization and Revenue from its Non-Opioid Pain Palliation Drug in Q2 2018 and Initiation of Multiple Pivotal Clinical Programs in 2018NEW YORK, February 1, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology...

Q BioMed Inc. Prices $5.5 Million Public Offering

Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018NEW YORK, January 30, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO) ("Q BioMed" or the "Company"), a commercial stage biotechnology acceleration development company is...